Potential Genetic Causes of Heterogeneity of Treatment Effects

American Journal of Medicine

Volumn 120, Issue 4 SUPPL., 2007, Pages

  Goldstein, David B ^a   Need, Anna C ^a   Singh, Rinki ^b   Sisodiya, Sanjay M ^b  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biologic characteristics; Genetics; Heterogeneity; Population characteristics; Population genetics

Indexed keywords

ACYLTRANSFERASE; ALDEHYDE DEHYDROGENASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CATECHOL METHYLTRANSFERASE; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2D6; DEBRISOQUINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOPAMINE; DOPAMINE TRANSPORTER; DRUG RECEPTOR; ENZYME; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; ION CHANNEL; NEUROLEPTIC AGENT; SULFOTRANSFERASE; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TOPIRAMATE; TYROSINE 3 MONOOXYGENASE;

AGE; ALCOHOL CONSUMPTION; ARTICLE; COGNITIVE DEFECT; DIET; DISEASE SEVERITY; DOPAMINE METABOLISM; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; EXERCISE; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNE SYSTEM; KIDNEY FUNCTION; LIFESTYLE; LIVER FUNCTION; PHARMACODYNAMICS; PHARMACOGENETICS; POPULATION GENETICS; PRIORITY JOURNAL; SEX; SMOKING; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE FACTORS; CLINICAL TRIALS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FEMALE; FRUCTOSE; GENETICS, POPULATION; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; RISK ASSESSMENT; SEX FACTORS; TREATMENT OUTCOME;

EID: 33947646865     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.02.004     Document Type: Article

References (39)

1. Spear B.B., Heath-Chiozzi M., and Huff J. Clinical application of pharmacogenetics. Trends Mol Med 7 (2001) 201-204
2. Greenfield S., Kravitz R., Duan N., and Kaplan S.H. Heterogeneity of treatment effects: implications for guidelines, payment and quality assessment. Am J Med 120 (2007) S3-S9
3. Fritz N., Glogau S., Hoffmann J., et al. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 6 (2005) 373-381
4. Kockelmann E., Elger C.E., and Helmstaedter C. Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res 54 (2003) 171-178
5. Lee S., Sziklas V., Andermann F., et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia 44 (2003) 339-347
6. Rorsman I., and Kallen K. Recovery of cognitive and emotional functioning following withdrawal of topiramate maintenance therapy. Seizure 10 (2001) 592-595
7. Thompson P.J., Baxendale S.A., Duncan J.S., and Sander J.W. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 69 (2000) 636-641
8. Han S.W., Kim T.Y., Jeon Y.K., et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 12 (2006) 2538-2544
9. Hamelin B.A., Turgeon J., Vallee F., et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 60 (1996) 512-521
10. Ereshefsky L., Riesenman C., and Lam Y.W. Antidepressant drug interactions and the cytochrome P450 system: the role of cytochrome P450 2D6. Clin Pharmacokinet 29 suppl 1 (1995) 10-18
11. Brosen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig 71 (1993) 1002-1009
12. Eap C.B., Bondolfi G., Zullino D., et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 21 (2001) 330-334
13. Whyte E.M., Romkes M., Mulsant B.H., et al. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry 21 (2006) 746-751
14. Steimer W., Zopf K., von Amelunxen S., et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 50 (2004) 1623-1633
15. Steimer W., Zopf K., von Amelunxen S., et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 51 (2005) 376-385
16. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5 (2005) 6-13
17. Kirchheiner J., Nickchen K., Bauer M., et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9 (2004) 442-473
18. Rogowski W. Current impact of gene technology on healthcare: a map of economic assessments. Health Policy 80 (2007) 340-357
19. Need A.C., Motulsky A.G., and Goldstein D.B. Priorities and standards in pharmacogenetic research. Nat Genet 37 (2005) 671-681
20. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3 (2002) 229-243
21. Johansson I., Oscarson M., Yue Q.Y., et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46 (1994) 452-459
22. Masimirembwa C., Persson I., Bertilsson L., Hasler J., and Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 42 (1996) 713-719
23. Tate S.K., and Goldstein D.B. Will tomorrow's medicines work for everyone?. Nat Genet 36 suppl (2004) S34-S42
24. Bakker P.R., van Harten P.N., and van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 83 (2006) 185-192
25. 108/158 Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 161 (2004) 1798-1805
26. Hedenmalm K., Guzey C., Dahl M.L., Yue Q.Y., and Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 26 (2006) 192-197
27. Matsumoto C., Shinkai T., De Luca V., et al. Association between three functional polymorphisms of the dopamine D2 receptor gene and polydipsia in schizophrenia. Int J Neuropsychopharmacol 8 (2005) 245-253
28. Zhao A.L., Zhao J.P., Zhang Y.H., et al. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci 115 (2005) 1539-1547
29. Arinami T., Gao M., Hamaguchi H., and Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 6 (1997) 577-582
30. Contini V., Marques F.Z., Garcia C.E., Hutz M.H., and Bau C.H. MAOA-uVNTR polymorphism in a Brazilian sample: further support for the association with impulsive behaviors and alcohol dependence. Am J Med Genet B Neuropsychiatr Genet 141 (2006) 305-308
31. Garpenstrand H., Ekblom J., Forslund K., Rylander G., and Oreland L. Platelet monoamine oxidase activity is related to MAOB intron 13 genotype. J Neural Transm 107 (2000) 523-530
32. Heinz A., Goldman D., Jones D.W., et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22 (2000) 133-139
33. Syvanen A.C., Tilgmann C., Rinne J., and Ulmanen I. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 7 (1997) 65-71
34. Wei J., Ramchand C.N., and Hemmings G.P. Possible association of catecholamine turnover with the polymorphic (TCAT)n repeat in the first intron of the human tyrosine hydroxylase gene. Life Sci 61 (1997) 1341-1347
35. Need A.C., Ahmadi K.R., Spector T.D., and Goldstein D.B. Obesity is associated with genetic variants that alter dopamine availability. Ann Hum Genet 70 (2006) 293-303
36. Sconce E.A., Khan T.I., Wynne H.A., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106 (2005) 2329-2333
37. Ahmadi K.R., Weale M.E., Xue Z.Y., et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet 37 (2005) 84-89
38. Shah P.R., hmad-Annuar A., Ahmadi K.R., et al. No association of DYNC1H1 with sporadic ALS in a case-control study of a northern European derived population: a tagging SNP approach. Amyotroph Lateral Scler Other Motor Neuron Disord 7 (2006) 46-56
39. Shephard N., John S., Cardon L., McCarthy M.I., and Zeggini E. Will the real disease gene please stand up?. BMC Genet 6 suppl 1 (2005) S66